UCB’s BIMZELX® (bimekizumab-bkzx) has been approved by the United States Food and Drug Administration (FDA). Notably, it is the first and only IL-17A and IL-17F inhibitor approved for treating adults with moderate to severe plaque psoriasis.
Learn More About BIMZELX® – Summary of Product Characteristics
Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira® (adalimumab), is now commercially available in the United States.
Sandoz announced that Hyrimoz® (adalimumab-adaz) injection is now available in the United States starting July 1.
Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.
